Cancer Immunotherapy Brings a Distinct Venous Thromboembolism Burden Into View
Venous thromboembolism has become one of the more clinically demanding complications to track in patients receiving cancer immunotherapy. A narrative review by Fowler and Pastores examines how thrombotic risk appears to differ across immune checkpoint inhibitors, CAR T-cell therapy, bispecific T-cell engagers, and related immune-based treatments. The central message is not that immunotherapy behaves like conventional chemotherapy, but that it may generate its own coagulation biology through immune activation, cytokine release, and inflammatory signaling. In practice, that means thrombosis can no longer be treated as a generic oncology adverse event with a one-size-fits-all prevention strategy.
The review places special emphasis on the expanding range of therapies now grouped under the immunotherapy umbrella. Each class appears to carry a different risk profile, and the mechanisms are not interchangeable. Immune checkpoint inhibition may amplify pre-existing inflammatory pathways, while CAR T-cell therapy introduces a separate hemostatic problem through cytokine release syndrome. Bispecific T-cell engagers add another layer of complexity because they intensify immune signaling in patients who are often already burdened by malignancy-related hypercoagulability. A single risk model built for cytotoxic chemotherapy cannot be assumed to perform well in this setting.
Inflammation, IL-8, and NET Formation Help Explain the Thrombotic Signal
Across real-world studies, the incidence of venous thromboembolism in patients receiving immune checkpoint inhibitors has varied widely. The spread in estimates reflects differences in study populations, tumor types, comorbidities, and ascertainment methods, but the review argues that biology likely contributes as well. One proposed pathway centers on interleukin-8-mediated inflammation, which may be intensified during immune activation. As inflammatory signaling rises, neutrophil extracellular traps can form and create a prothrombotic surface that encourages clot generation.
This mechanism fits with the clinical pattern seen in cancer generally: malignancy already primes coagulation, and immunotherapy may add a second inflammatory push. NET formation is especially relevant because it links innate immune activation to platelet adhesion, endothelial dysfunction, and fibrin deposition. In a patient who is responding immunologically to therapy, the same immune momentum that targets tumor tissue may also push the vascular system toward thrombosis. The review does not present this as a settled pathway, but the mechanistic plausibility is strong enough to matter at the bedside.
One sentence captures the clinical tension: immune activation can help treat the cancer while simultaneously aggravating the coagulation system.
CAR T-Cell Therapy Creates a Different Balance of Thrombosis and Bleeding
CAR T-cell therapy stands apart from checkpoint blockade because its hemostatic complications can run in two directions at once. The review describes thrombotic and bleeding risks that may occur concurrently, particularly in the setting of cytokine release syndrome. That syndrome can destabilize vascular integrity, alter coagulation factors, and create a shifting balance between clot formation and hemorrhage. The result is not simply a higher thrombotic risk, but a more unstable hemostatic environment overall.
This has direct implications for inpatient management. Patients receiving CAR T-cell therapy often require close monitoring during periods of acute immune toxicity, when fever, hypotension, and systemic inflammation may coincide with laboratory and clinical signs that could point in either direction. A standard thromboprophylaxis approach may be too blunt for that setting. The review’s framing makes clear that hemostasis in CAR T recipients is less a static risk factor than a moving target shaped by immune toxicity.
Current Risk Scores Miss the Biology of Immunotherapy
Existing VTE risk assessment tools have limited predictive value in patients receiving immunotherapies for cancer. The review does not treat this as a minor technical flaw. It reflects a larger mismatch between traditional oncology risk models and the biology of immune-based treatment. Conventional tools were built around variables such as tumor burden, immobilization, prior thrombosis, and chemotherapy exposure. Those factors still matter, but they do not fully capture immune activation, cytokine surges, or therapy-specific inflammatory effects.
As immunotherapy use expands, risk stratification will need to evolve beyond static clinical checklists. A patient starting an immune checkpoint inhibitor may have modest baseline risk by older scoring systems, yet still develop thrombosis through an inflammatory cascade that the score never measures. Another patient on CAR T therapy may swing rapidly between clotting and bleeding depending on the intensity of cytokine release syndrome. A model that ignores those dynamics is unlikely to guide prophylaxis with enough precision.
Why Tailored Thromboprophylaxis Has Become the Next Question
The review ends where contemporary practice has to end for now: with the need for immunotherapy-specific thromboprophylaxis strategies. Evidence-based prevention remains limited, and there is no universal approach that fits all immune therapies. Patients may need different surveillance and prevention frameworks depending on whether they are receiving checkpoint inhibitors, CAR T-cell therapy, or bispecific agents. Tumor type, prior thrombosis, and the presence of inflammatory toxicity all likely influence the decision, but the field lacks a validated method for integrating those variables.
That gap is especially important because thrombotic complications can interrupt cancer treatment, worsen hospitalization risk, and complicate already fragile treatment courses. When thrombosis appears during immunotherapy, clinicians must decide not only how to treat the event, but whether future immune treatment can continue safely. Those decisions are harder when risk prediction remains imprecise.
The review points toward three research priorities: better mechanistic studies, immunotherapy-specific prediction tools, and prophylaxis strategies tailored to the immune treatment class and toxicity profile. Until those tools exist, venous thromboembolism remains an underdefined hazard in a field otherwise defined by therapeutic innovation. The unanswered practical problem is how to prevent clotting without worsening bleeding in patients whose immune therapy is already altering vascular and inflammatory biology.